Therefore, next, the estrogen dependency of SVIP expression in ER+ breast cancer cells was evaluated using 17β-estradiol (E2), and our results revealed that E2 did not cause any significant alterations in SVIP expression levels in MCF-7, T47D, and ZR75-1 cells (Figure 5B). This evidence concerns the gene SVIP and breast cancer.